The use of a vasoconstrictor to improve tumour blood flow in intra-arterial chemotherapy: Preliminary report

Harvey A. Ziessman, Arlene A. Fqrastiere, Richard H. Wheeler, Jack E. Juni, Richard L. Wahl, Barbara R. Medvec, Robert J. Ackermann, Shan R. Baker, James H. Thrall, John W. Keyes

Research output: Contribution to journalArticle

Abstract

The effectiveness of intra-arterial chemotherapy is dependent on a high tumour to normal blood flow ratio (T/NT). This report demonstrates the use of a vasoconstrictor (NE) to improve the relative blood flow to head and neck tumours by causing vasoconstriction and decreased blood flow to normal soft tissue. Five quantitative planar Tc-MAA perfusion studies were performed on three patients with increasing dose rates of norepinephrine (NE) to determine the optimal dose in each patient that would produce the best T/NT. All patients demonstrated a change in perfusion pattern with increasing dose rates (0.1 to 15 μg min-1), although there was considerable variation between patients. Quantitative SPECT was performed on two patients. In one, there was a 35% increase in the T/NT and a 16% decrease in arteriovenous (A-V) shunting to the lung.

Original languageEnglish (US)
Pages (from-to)777-786
Number of pages10
JournalNuclear medicine communications
Volume6
Issue number12
DOIs
StatePublished - Dec 1985

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The use of a vasoconstrictor to improve tumour blood flow in intra-arterial chemotherapy: Preliminary report'. Together they form a unique fingerprint.

  • Cite this

    Ziessman, H. A., Fqrastiere, A. A., Wheeler, R. H., Juni, J. E., Wahl, R. L., Medvec, B. R., Ackermann, R. J., Baker, S. R., Thrall, J. H., & Keyes, J. W. (1985). The use of a vasoconstrictor to improve tumour blood flow in intra-arterial chemotherapy: Preliminary report. Nuclear medicine communications, 6(12), 777-786. https://doi.org/10.1097/00006231-198512000-00006